IBKS No2 SPAC (204840) - Net Assets

Latest as of September 2025: ₩20.01 Billion KRW ≈ $13.56 Million USD

Based on the latest financial reports, IBKS No2 SPAC (204840) has net assets worth ₩20.01 Billion KRW (≈ $13.56 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩46.46 Billion ≈ $31.49 Million USD) and total liabilities (₩26.45 Billion ≈ $17.93 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are IBKS No2 SPAC's assets to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets ₩20.01 Billion
% of Total Assets 43.07%
Annual Growth Rate 22.42%
5-Year Change 37.4%
10-Year Change N/A
Growth Volatility 166.09

IBKS No2 SPAC - Net Assets Trend (2015–2024)

This chart illustrates how IBKS No2 SPAC's net assets have evolved over time, based on quarterly financial data. Also explore IBKS No2 SPAC (204840) total assets for the complete picture of this company's asset base.

Annual Net Assets for IBKS No2 SPAC (2015–2024)

The table below shows the annual net assets of IBKS No2 SPAC from 2015 to 2024. For live valuation and market cap data, see 204840 market cap overview.

Year Net Assets Change
2024-12-31 ₩19.67 Billion
≈ $13.33 Million		 +60.13%
2023-12-31 ₩12.28 Billion
≈ $8.32 Million		 -23.67%
2022-12-31 ₩16.09 Billion
≈ $10.90 Million		 -4.50%
2021-12-31 ₩16.85 Billion
≈ $11.42 Million		 +17.71%
2020-12-31 ₩14.31 Billion
≈ $9.70 Million		 +506.12%
2019-12-31 ₩2.36 Billion
≈ $1.60 Million		 -69.79%
2018-12-31 ₩7.82 Billion
≈ $5.30 Million		 +31.70%
2017-12-31 ₩5.94 Billion
≈ $4.02 Million		 -30.73%
2016-12-31 ₩8.57 Billion
≈ $5.81 Million		 +169.20%
2015-12-31 ₩3.18 Billion
≈ $2.16 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to IBKS No2 SPAC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 2118089260000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock ₩7.70 Billion 39.13%
Other Components ₩34.08 Billion 173.29%
Total Equity ₩19.67 Billion 100.00%

IBKS No2 SPAC Competitors by Market Cap

The table below lists competitors of IBKS No2 SPAC ranked by their market capitalization.

Company Market Cap
Baolong International Co Ltd
TW:1906
 $52.33 Million
SundayToz Corp
KQ:123420
 $52.37 Million
Sea & Land Integrated Co
TWO:5603
 $52.37 Million
C-Tech United
TWO:3625
 $52.38 Million
ARRAS MINERALS CORP.
F:9RJ
 $52.33 Million
Widodo Makmur Unggas Tbk PT
JK:WMUU
 $52.32 Million
Silvano Fashion Group AS
WAR:SFG
 $52.31 Million
Universal Textile Co Ltd
TW:1445
 $52.28 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in IBKS No2 SPAC's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 12,282,299,520 to 19,667,919,320, a change of 7,385,619,800 (60.1%).
  • Net loss of 2,337,462,830 reduced equity.
  • Share repurchases of 9,279,742,740 reduced equity.
  • New share issuances of 9,279,742,730 increased equity.
  • Other factors increased equity by 9,723,082,640.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income ₩-2.34 Billion -11.88%
Share Repurchases ₩9.28 Billion -47.18%
Share Issuances ₩9.28 Billion +47.18%
Other Changes ₩9.72 Billion +49.44%
Total Change ₩- 60.13%

Book Value vs Market Value Analysis

This analysis compares IBKS No2 SPAC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.91x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 3.75x to 3.91x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2016-12-31 ₩266.75 ₩1000.00 x
2017-12-31 ₩176.05 ₩1000.00 x
2018-12-31 ₩205.51 ₩1000.00 x
2019-12-31 ₩66.00 ₩1000.00 x
2020-12-31 ₩303.21 ₩1000.00 x
2021-12-31 ₩272.40 ₩1000.00 x
2022-12-31 ₩259.09 ₩1000.00 x
2023-12-31 ₩196.98 ₩1000.00 x
2024-12-31 ₩255.54 ₩1000.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently IBKS No2 SPAC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -11.88%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -8.97%
  • • Asset Turnover: 0.61x
  • • Equity Multiplier: 2.16x
  • Recent ROE (-11.88%) is above the historical average (-52.97%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2015 0.62% 0.26% 0.73x 3.29x ₩-252.78 Million
2016 -64.13% -118.53% 0.38x 1.44x ₩-6.35 Billion
2017 -71.38% -175.52% 0.16x 2.53x ₩-4.83 Billion
2018 -68.44% -66.88% 0.25x 4.04x ₩-6.13 Billion
2019 -233.54% -51.99% 0.40x 11.24x ₩-5.75 Billion
2020 -23.45% -28.00% 0.34x 2.44x ₩-4.79 Billion
2021 -22.12% -30.00% 0.39x 1.89x ₩-5.41 Billion
2022 -4.91% -4.72% 0.41x 2.54x ₩-2.40 Billion
2023 -30.52% -14.40% 0.65x 3.25x ₩-4.98 Billion
2024 -11.88% -8.97% 0.61x 2.16x ₩-4.30 Billion

Industry Comparison

This section compares IBKS No2 SPAC's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $551,740,764,467
  • Average return on equity (ROE) among peers: 3.91%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
IBKS No2 SPAC (204840) ₩20.01 Billion 0.62% 1.32x $52.33 Million
Dongwha Pharm.Co.Ltd (000020) $360.13 Billion 4.96% 0.24x $110.26 Million
Yuhan Corp. (000100) $1.85 Trillion 10.44% 0.30x $4.32 Billion
Yuhan Corp Preferred (000105) $1.65 Trillion 3.48% 0.32x $56.81 Million
Yuyu Pharma (000220) $71.49 Billion -10.45% 0.42x $45.40 Million
Yuyu Pharma Inc (000225) $73.73 Billion -0.34% 0.41x $17.61 Million
Yuyu Pharma Inc (000227) $78.29 Billion 7.52% 0.42x $43.13 Million
Ildong Holdings Co Ltd (000230) $172.99 Billion 13.36% 0.64x $68.95 Million
Samil Pharm (000520) $70.03 Billion 11.32% 0.65x $128.33 Million
Donga Socio Holdings (000640) $985.04 Billion 6.12% 0.72x $418.42 Million
Jw Pharmac (001060) $207.47 Billion -7.35% 1.65x $465.32 Million

About IBKS No2 SPAC

KQ:204840 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$52.33 Million
₩77.22 Billion KRW
Market Cap Rank
#21768 Global
#1424 in Korea
Share Price
₩1000.00
Change (1 day)
+1.01%
52-Week Range
₩990.00 - ₩1320.00
All Time High
₩8655.23
Categories
Companies in Korea Drug Manufacturers - Specialty & Generic
About

GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disea… Read more